| 4.18 -0.25 (-5.64%) | 01-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.48 | 1-year : | 6.4 |
| Resists | First : | 4.69 | Second : | 5.48 |
| Pivot price | 4.07  |
|||
| Supports | First : | 3.82 | Second : | 3.28 |
| MAs | MA(5) : | 4.23 |
MA(20) : | 3.91 |
| MA(100) : | 4.4 |
MA(250) : | 3.23 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 79.4 |
D(3) : | 74.6 |
| RSI | RSI(14): 53.6 |
|||
| 52-week | High : | 6.94 | Low : | 1.11 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PRME ] has closed below upper band by 40.0%. Bollinger Bands are 28.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.41 - 4.44 | 4.44 - 4.47 |
| Low: | 4.03 - 4.05 | 4.05 - 4.08 |
| Close: | 4.14 - 4.18 | 4.18 - 4.22 |
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Thu, 22 Jan 2026
Prime Medicine (NASDAQ:PRME) Shares Up 10.5% - Here's Why - MarketBeat
Thu, 22 Jan 2026
Prime Medicine (NYSE:PRME) Shares Up 12.4% - Time to Buy? - MarketBeat
Mon, 12 Jan 2026
Prime Medicine, Inc. Updates on Prime Editing Developments - TradingView
Mon, 12 Jan 2026
Prime Medicine updates corporate strategy for Prime Editing platform - TipRanks
Wed, 07 Jan 2026
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Wed, 31 Dec 2025
LifeSci Capital Initiates Prime Medicine (PRME), Highlights One-and-Done Potential in Liver and Lung Diseases - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 181 (M) |
| Held by Insiders | 1.0434e+008 (%) |
| Held by Institutions | 17.6 (%) |
| Shares Short | 19,670 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.968e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 405.9 % |
| Return on Equity (ttm) | -35.6 % |
| Qtrly Rev. Growth | 5.98e+006 % |
| Gross Profit (p.s.) | 178.71 |
| Sales Per Share | -41.31 |
| EBITDA (p.s.) | -5.6636e+007 |
| Qtrly Earnings Growth | -1.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -109 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.11 |
| Price to Cash Flow | 12.35 |
| Dividend | 0 |
| Forward Dividend | 2.567e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|